An experimental treatment that uses CRISPR to edit genes directly inside the body has just succeeded in a Phase 3 trial — a first for the technology — putting it on track for a potential FDA approval …
Lilly’s M&A team strikes again with $2.3bn Ajax takeover
With the ink barely dry on a deal to buy Kelonia, Lilly has signed a $2.3bn deal to acquire Ajax Therapeutics and its JAK2 blood